Monday, March 20, 2017
4:00 PM - 5:00 PM
Where: Ward Building, 5-230, 303 E. Chicago Avenue, Chicago, IL 60611 map it
Audience: Faculty/Staff - Student - Public - Post Docs/Docs - Graduate Students
Category: Lectures & Meetings
The Department of Pharmacology is pleased to welcome Dr. Leon Huang, Ph.D., Senior Scientist, Abbvie Oncology Discovery.
The following, is an overview of this seminar, as described by Dr. Huang:
The idiotypic determinant (Id) of the immunoglobulin expressed by a B-cell malignancy can serve as a tumor antigen but is weakly immunogenic. We demonstrated that fusing CTLA-4 to Id represents an effective approach to prime antitumor immunities against B cell lymphoma and may be applicable to the treatment of other human cancers. IFN-alpha has potent immunostimulatory and antiproliferative effects against B-cell malignancies but its clinical utility is limited by systemic toxicity. We constructed a novel fusion protein consisting of anti-CD20 and IFN-alpha (IGN002) and demonstrated that IGN002 exhibited selective targeting and superior anti-tumor efficacy than rituximab. The results support the development of IGN002 for B-cell NHL treatment and first-in-human clinical studies are ongoing in the United States.